Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 61 for lung cancer

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

    Rochester, MN

  2. DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan

    Jacksonville, FL

  3. A Study to Evaluate Durvalumab plus Topotecan or Lurbinectedin in Patients with Small Cell Lung Cancer

    Rochester, MN

  4. Needle-based Confocal Laser Endomicroscopy Guided For Lung Cancer Diagnosis: A Randomized Controlled Trial

    Jacksonville, FL, Rochester, MN

  5. Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

    Jacksonville, FL

  6. A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer

    Rochester, MN

  7. Neoadjuvant dual checkpoint blockade with PD1 and LAG-3 inhibition in resectable Non-small cell lung Cancer

    Rochester, MN

  8. Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

    Rochester, MN

  9. Synergy with Grid Therapy and Immune Checkpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer

    Rochester, MN

  10. A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

    Jacksonville, FL

.

Mayo Clinic Footer